AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38788175 — intervention group
Group type: COMPARATOR
Intervention: Usual care in good-grade aSAH (N = 241)
Number of subjects: 812
Study 38788175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment in poor-grade aSAH (N = 162)
Number of subjects: 812
Study 38788175 — intervention group
Group type: COMPARATOR
Intervention: Usual care in poor-grade aSAH (N = 176)
Number of subjects: 812
Study 38788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior wall tumors (TURBT)
Number of subjects: 118477
Study 38788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dome tumors (TURBT)
Number of subjects: 118477
Study 38788195 — intervention group
Group type: COMPARATOR
Intervention: Dome tumors (Partial cystectomy)
Number of subjects: 118477
Study 38788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior wall tumors (SEER cohort)
Number of subjects: 118477
Study 38788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dome tumors (SEER cohort)
Number of subjects: 118477
Study 38788261 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 1400
Study 38788261 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1400
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - having fruits and vegetables (F&V) at home
Number of subjects: 964
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - increasing home availability of F&V
Number of subjects: 964
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - not having sweets or salty snacks available at home
Number of subjects: 964
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - having F&V availability
Number of subjects: 964
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - never having soft drinks at home
Number of subjects: 964
Study 38788341 — intervention group
Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - never being permissive about soft drink consumption
Number of subjects: 964
Study 38788664 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50-200 mg/day
Number of subjects: 803
Study 38788664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 803
Study 38788744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir plus dolutegravir
Number of subjects: 828
Study 38788744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir with tenofovir disoproxil fumarate plus either lamivudine or emtricitabine
Number of subjects: 828
Study 38788744 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir plus two NRTIs
Number of subjects: 828
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: TEER with MitraClip device plus guideline-directed medical therapy (GDMT)
Number of subjects: 293
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat mitral valve intervention (RMVI)
Number of subjects: 293
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI
Number of subjects: 293
Study 38788821 — intervention group
Group type: COMPARATOR
Intervention: Patients without RMVI
Number of subjects: 293
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI pre-RMVI
Number of subjects: 293
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI post-RMVI
Number of subjects: 293
Study 38788821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate ratio of HFH after RMVI
Number of subjects: 293
Study 38788861 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 SC 120 mg every 2 weeks until week 54
Number of subjects: 944
Study 38788861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 944
Study 38788904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of 1 g of tranexamic acid (TXA) dissolved in 50 mL of 0.9% saline at multiple sites
Number of subjects: 60
Study 38788904 — intervention group
Group type: COMPARATOR
Intervention: 60 mL saline injection (Control)
Number of subjects: 60
Study 38788907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole 2.5 mg/day
Number of subjects: 617
Study 38788915 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic FMT
Number of subjects: 72
Study 38788915 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous FMT
Number of subjects: 72
Study 38789080 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial follow-up survey
Number of subjects: 0
Study 38789080 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 0
Study 38789134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g corresponding to 70 mg of elemental iron) once daily for 12 weeks
Number of subjects: 0
Study 38789134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar in colour, smell, and size to ferrous iron) once daily for 12 weeks
Number of subjects: 0
Study 38789134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g)
Number of subjects: 0
Study 38789134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38789142 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive e-alcohol therapy
Number of subjects: 379
Study 38789325 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-guided stent size
Number of subjects: 65
Study 38789325 — intervention group
Group type: COMPARATOR
Intervention: OCT lumen-guided stent size
Number of subjects: 65
Study 38789325 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 65
Study 38789363 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of beta-blockers
Number of subjects: 1789
Study 38789460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy (gemcitabine and cisplatin plus pembrolizumab)
Number of subjects: 39
Study 38789460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy (NAC-ICI)
Number of subjects: 39
Study 38789460 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-9
Number of subjects: 39
Study 38789460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor IL-8 signature and stroma-rich subtype
Number of subjects: 39
Study 38789602 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.03 mcg/kg/min)
Number of subjects: 196
Study 38789602 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (0.4 mcg/kg/min)
Number of subjects: 196
Study 38789635 — intervention group
Group type: COMPARATOR
Intervention: BI 685509 (1.0, 2.5, or 5.0 mg)
Number of subjects: 84
Study 38789635 — intervention group
Group type: COMPARATOR
Intervention: BI 685509 (1 mg qd, 2.5 mg bid, 5.0 mg qd, 3.0 mg tid, 4.0 mg tid)
Number of subjects: 84
Study 38789635 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 685509
Number of subjects: 84
Study 38789642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 78
Study 38789642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 38789656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose geranium in sesame oil (RG) nasal spray, administered twice daily for 2 weeks
Number of subjects: 106
Study 38789656 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (IS) nasal spray, administered twice daily for 2 weeks
Number of subjects: 106
Study 38789848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788)
Number of subjects: 0
Study 38789896 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral-compartment-first technique
Number of subjects: 704
Study 38789924 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Number of subjects: 812
Study 38789924 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus optional endocrine therapy (ET)
Number of subjects: 812
Study 38789927 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-led implementation of the Cardiovascular Assessment Screening Program (CASP)
Number of subjects: 167
Study 38789927 — intervention group
Group type: COMPARATOR
Intervention: Usual care by nurse practitioners (control group)
Number of subjects: 167
Study 38789927 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-led implementation of CASP
Number of subjects: 167
Study 38789966 — intervention group
Group type: EXPERIMENTAL
Intervention: CCP clinical audits
Number of subjects: 2867
Study 38789966 — intervention group
Group type: COMPARATOR
Intervention: VINCat Programme
Number of subjects: 2867
Study 38789992 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous or allogenic adipose tissue mesenchymal stromal cells (AT-MSC) combined with tricalcium phosphate biomaterial
Number of subjects: 12
Study 38789992 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow mesenchymal stem cells (BM-MSC)
Number of subjects: 12
Study 38790007 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percent in aSAH patients
Number of subjects: 59
Study 38790007 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat mass in aSAH patients
Number of subjects: 59
Study 38790008 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid maintenance treatment (OMT)
Number of subjects: 131
Study 38790040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 269
Study 38790040 — intervention group
Group type: COMPARATOR
Intervention: Placebo-to-tofacitinib
Number of subjects: 269
Study 38790045 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit intervention and implementation support intervention
Number of subjects: 10000
Study 38790045 — intervention group
Group type: COMPARATOR
Intervention: Audit intervention only
Number of subjects: 10000
Study 38790045 — intervention group
Group type: COMPARATOR
Intervention: No intervention offered
Number of subjects: 10000
Study 38790057 — intervention group
Group type: EXPERIMENTAL
Intervention: APG-1387 and anti-PD-1 antibody
Number of subjects: 4
Study 38790057 — intervention group
Group type: EXPERIMENTAL
Intervention: APG-1387
Number of subjects: 4
Study 38790057 — intervention group
Group type: COMPARATOR
Intervention: Blocking IL-12 secretion
Number of subjects: 4
Study 38790505 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week Mellow Babies programme
Number of subjects: 38
Study 38790505 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting list)
Number of subjects: 38
Study 38790900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting BiOSS LIM C stent
Number of subjects: 230
Study 38790900 — intervention group
Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents (rDESs)
Number of subjects: 230
Study 38793103 — intervention group
Group type: EXPERIMENTAL
Intervention: Music as a motivating factor to promote physical activity
Number of subjects: 0
Study 38793103 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological signals measurement
Number of subjects: 0
Study 38793103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and physical activity promotion routines
Number of subjects: 0
Study 38793748 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), administered intramuscularly 14 days apart
Number of subjects: 75
Study 38793748 — intervention group
Group type: COMPARATOR
Intervention: Saline/placebo (two doses administered intramuscularly 14 days apart)
Number of subjects: 75
Study 38793748 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2)
Number of subjects: 75
Study 38794639 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet (KD) for 4 months
Number of subjects: 7
Study 38794715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (5:2 Diet) plus Mediterranean dietary pattern (IER + MED)
Number of subjects: 0
Study 38794715 — intervention group
Group type: COMPARATOR
Intervention: Standard Mediterranean dietary pattern with daily energy restriction (DER + MED)
Number of subjects: 0
Study 38794734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA), isokinetic, and ultrasound parameters
Number of subjects: 50
Study 38794734 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle (cut-off: 5.10° men)
Number of subjects: 50
Study 38794734 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak torque, total work, and mean power in leg extension
Number of subjects: 50
Study 38794734 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm muscle thickness
Number of subjects: 50
Study 38794741 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic treatment
Number of subjects: 202
Study 38794741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 38794892 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy in MagnetisMM-2
Number of subjects: 16
Study 38794892 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy in MagnetisMM-3
Number of subjects: 16
Study 38794906 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR+LET
Number of subjects: 92
Study 38794906 — intervention group
Group type: COMPARATOR
Intervention: ACLR
Number of subjects: 92
Study 38794945 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm potassium titanyl-phosphate (KTP) laser
Number of subjects: 35
Study 38794945 — intervention group
Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 35
Study 38795055 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenciguat
Number of subjects: 0
Study 38795055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous LAAC using single (Watchman 2.5/FLX) and double (Amplatzer Cardiac Plug or Amulet) devices
Number of subjects: 1023
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous LAAC procedures
Number of subjects: 1023
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-closure left atrial appendage devices
Number of subjects: 1023
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1023
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) at baseline
Number of subjects: 1023
Study 38795087 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 1023
Study 38795108 — intervention group
Group type: EXPERIMENTAL
Intervention: TEER + guideline-directed medical therapy (GDMT)
Number of subjects: 347
Study 38795108 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 347
Study 38795110 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 30
Study 38795110 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 30
Study 38795120 — intervention group
Group type: COMPARATOR
Intervention: Standard immunochemotherapy followed by rituximab maintenance (standard arm)
Number of subjects: 807
Study 38795120 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard immunochemotherapy followed by response-adapted post-induction management (experimental arm)
Number of subjects: 807
Study 38795650 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial Description Model
Number of subjects: 103
Study 38795703 — intervention group
Group type: EXPERIMENTAL
Intervention: COX inhibitors plus anti-PD-1 therapy
Number of subjects: 30
Study 38795716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 2 weeks
Number of subjects: 1014
Study 38795716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks
Number of subjects: 1014
Study 38795716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1014
Study 38795716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (all dosing regimens)
Number of subjects: 1014
Study 38795716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1014
Study 38795747 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE eating behavior risk score
Number of subjects: 76
Study 38795747 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 76
Study 38795747 — intervention group
Group type: COMPARATOR
Intervention: Children with high maternal BMI (≥30 kg/m²)
Number of subjects: 76
Study 38795859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (IL-6R blockade)
Number of subjects: 0
Study 38795859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38796193 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (300 mg once a day for 14 days in a 28-day cycle)
Number of subjects: 86
Study 38796193 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice standard therapy (ICT; gemcitabine, bendamustine, or romidepsin)
Number of subjects: 86
Study 38796326 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rotavirus inactivated vaccine
Number of subjects: 96
Study 38796326 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose rotavirus inactivated vaccine
Number of subjects: 96
Study 38796326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rotavirus inactivated vaccine
Number of subjects: 96
Study 38796326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 38796422 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT) for 6 cycles
Number of subjects: 47
Study 38796422 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT for 6 cycles
Number of subjects: 47
Study 38796495 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX gadolinium-based nanoparticle
Number of subjects: 23
Study 38796500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 36
Study 38796500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics and mechanical bowel preparation
Number of subjects: 36
Study 38796500 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study 38796564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Number of subjects: 0
Study 38796619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept
Number of subjects: 159
Study 38796619 — intervention group
Group type: COMPARATOR
Intervention: 2 mg Aflibercept
Number of subjects: 159
Study 38796653 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 17604
Study 38796653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study 38796655 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (monoclonal antibody targeting IL-6 ligand)
Number of subjects: 0
Study 38796655 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38797114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidomain intervention including risk factors assessment, education, antiemetics, dietary strategies, and relaxation therapy
Number of subjects: 92
Study 38797114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidomain intervention
Number of subjects: 92
Study 38797114 — intervention group
Group type: COMPARATOR
Intervention: Usual care of CINV (control group)
Number of subjects: 92
Study 38797183 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week)
Number of subjects: 556
Study 38797183 — intervention group
Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 556
Study 38797183 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (two intramuscular injections at enrolment and at 2 months)
Number of subjects: 556
Study 38797183 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 556
Study 38797190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/kg intravenously on day 2 or 3, then once every 3 weeks for 2 years) + low-dose, single-fraction radiotherapy (8 Gy/1 fx)
Number of subjects: 25
Study 38797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin (Pen V arm, twice daily oral penicillin)
Number of subjects: 1004
Study 38797460 — intervention group
Group type: COMPARATOR
Intervention: Benzathine Benzyl Penicillin G (BPG arm, every-28-day intramuscular penicillin)
Number of subjects: 1004
Study 38797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin (Pen V arm)
Number of subjects: 1004
Study 38797460 — intervention group
Group type: COMPARATOR
Intervention: Benzathine Benzyl Penicillin G (BPG arm)
Number of subjects: 1004
Study 38797482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-rich vegetable juice providing low (13.1 mg), medium (23.9 mg), and high (31.0 mg) daily total carotenoid doses for 8 weeks.
Number of subjects: 80
Study 38797481 — intervention group
Group type: COMPARATOR
Intervention: CON (dry blend)
Number of subjects: 9
Study 38797481 — intervention group
Group type: EXPERIMENTAL
Intervention: EXT (HME blend)
Number of subjects: 9
Study 38797490 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF + KI
Number of subjects: 112
Study 38797490 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (SDF + KI + GIC)
Number of subjects: 112
Study 38797635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index-guided therapy (using intravenous fluids and dobutamine)
Number of subjects: 318
Study 38797635 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 318
Study 38797767 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic one-trocar-assisted pyeloplasty (OTAP)
Number of subjects: 70
Study 38797835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate and energy-restricted (LCER) diet (Pharm-TCR: <50 g carbohydrates; ~850-1100 kcal/day; n=20)
Number of subjects: 36
Study 38797835 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU; n=16)
Number of subjects: 36
Study 38797872 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated prognostic CDS
Number of subjects: 536